Literature DB >> 15191039

Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis.

Romain Lazor1, Dominique Valeyre, Jacques Lacronique, Benoît Wallaert, Thierry Urban, Jean-François Cordier.   

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) is a rare interstitial disorder affecting exclusively women, and leading to progressive deterioration of lung function. The disease course is highly variable from one patient to another, but no clinical predictor of rapid disease progression is currently available. To identify clinical variables, which could detect patients at risk for rapid lung function decline, we searched for correlations between the rate of forced expiratory volume in 1 s (FEV1) decline and clinical features at diagnosis in a retrospective series of 31 cases of LAM followed for > or = 1 yr. The mean FEV1 decline was 106+/-143 ml/yr or 3.4+/-4.6% predicted FEV1/yr. Among clinical features at diagnosis, only initial values of carbon monoxide transfer factor (TLCO, P = 0.006) and carbon monoxide transfer coefficient (KCO, P = 0.0001) were significantly correlated with the rate of FEV1 decline. Lung volumes and FEV1/forced vital capacity ratio at diagnosis were not predictive of rapid decline. No effect of previous smoking, contraceptive use or pregnancy on FEV1 decline could be detected. We conclude that low TLCO and KCO at the time of diagnosis are the best clinical predictors of rapid FEV1 decline in patients with LAM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191039     DOI: 10.1016/j.rmed.2003.11.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

2.  Emerging clinical picture of lymphangioleiomyomatosis.

Authors:  M M Cohen; S Pollock-BarZiv; S R Johnson
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

3.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

4.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

Review 5.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

Review 6.  Lymphangioleiomyomatosis - a wolf in sheep's clothing.

Authors:  Elizabeth P Henske; Francis X McCormack
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

7.  Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients.

Authors:  C Daccord; V Cottin; G Prévot; Y Uzunhan; J F Mornex; P Bonniaud; R Borie; A Briault; M A Collonge-Rame; B Crestani; G Devouassoux; O Freynet; A Gondouin; P A Hauss; C Khouatra; S Leroy; S Marchand-Adam; C Marquette; D Montani; J M Naccache; G Nadeau; N Poulalhon; M Reynaud-Gaubert; M Salaun; B Wallaert; J F Cordier; M Faouzi; R Lazor
Journal:  Orphanet J Rare Dis       Date:  2020-05-24       Impact factor: 4.123

8.  Air travel and incidence of pneumothorax in lymphangioleiomyomatosis.

Authors:  Cynthia Gonano; Jérôme Pasquier; Cécile Daccord; Simon R Johnson; Sergio Harari; Violette Leclerc; Lucy Falconer; Eleonora Miano; Jean-François Cordier; Vincent Cottin; Romain Lazor
Journal:  Orphanet J Rare Dis       Date:  2018-12-13       Impact factor: 4.123

9.  Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients.

Authors:  Angelo M Taveira-DaSilva; Patricia Julien-Williams; Amanda M Jones; Mario Stylianou; Joel Moss
Journal:  Eur Respir J       Date:  2018-04-19       Impact factor: 16.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.